Analyst Price Targets — AQST
Latest News for AQST
SAN DIEGO--(BUSINESS WIRE)---- $AOST #Aquestive--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients' lives through innovative science and…
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi and Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) between June 16, 2025 to January 8, 2026, inclusive.
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).…
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AQST.
U.S. House Trading
No House trades found for AQST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.